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Abstract
Mammalian target of rapamycin (mTOR)/S6K1 signalling emerges as a critical regulator of aging. Yet, a role of mTOR/S6K1 in
aging-associated vascular endothelial dysfunction remains unknown. In this study, we investigated the role of S6K1 in
aging-associated endothelial dysfunction and effects of the polyphenol resveratrol on S6K1 in aging endothelial cells. We
show here that senescent endothelial cells displayed higher S6K1 activity, increased superoxide production and decreased
bioactive nitric oxide (NO) levels than young endothelial cells, which is contributed by eNOS uncoupling. Silencing S6K1 in
senescent cells reduced superoxide generation and enhanced NO production. Conversely, over-expression of a
constitutively active S6K1 mutant in young endothelial cells mimicked endothelial dysfunction of the senescent cells
through eNOS uncoupling and induced premature cellular senescence. Like the mTOR/S6K1 inhibitor rapamycin, resveratrol
inhibited S6K1 signalling, resulting in decreased superoxide generation and enhanced NO levels in the senescent cells.
Consistent with the data from cultured cells, an enhanced S6K1 activity, increased superoxide generation, and decreased
bioactive NO levels associated with eNOS uncoupling were also detected in aortas of old WKY rats (aged 20–24 months) as
compared to the young animals (1–3 months). Treatment of aortas of old rats with resveratrol or rapamycin inhibited S6K1
activity, oxidative stress, and improved endothelial NO production. Our data demonstrate a causal role of the hyperactive
S6K1 in eNOS uncoupling leading to endothelial dysfunction and vascular aging. Resveratrol improves endothelial function
in aging, at least in part, through inhibition of S6K1. Targeting S6K1 may thus represent a novel therapeutic approach for
aging-associated vascular disease.
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Introduction
Aging is a dominant risk factor for cardiovascular disease [1].
One of the important features of vascular aging is endothelial
dysfunction characterized by decreased vasoprotective endothelial
nitric oxide (NO) bioavailability resulting from numerous
mechanisms including oxidative stress [2]. Excessive generation
of reactive oxygen species (ROS) such as superoxide anion in the
aging vasculature inactivates NO [2,3], leading to endothelial
dysfunction in aging [3,4]. However, the source and mechanisms
of enhanced oxidative stress in endothelial aging remain
incompletely understood.
Evidence is emerging that mTOR/S6K1 signalling is an
important regulator of aging [5] and aging-associated disorders
including cardiovascular diseases [6]. Early studies demonstrated
that inhibition of mTOR signalling is capable of extending lifespan
in invertebrates [7–11]. These observations have been recently
extended to mice [12–14]. Studies also suggest that lifespan
extension by dietary restriction in several species including mice is
possibly mediated by reduction of mTOR/S6K1 signalling [6].
mTOR is an evolutionarily conserved serine/threonine protein
kinase which integrates multiple signalling pathways regulating
gene expression involved in metabolism, cell survival, and cell
proliferation [15]. With other molecular components, mTOR
forms two structurally and functionally distinct complexes namely
mTORC1 and mTORC2. mTORC1 regulates cell growth
through S6K1 and eIF-4E–binding protein 1 (4E-BP1), is sensitive
to the immunosuppressant rapamycin, whereas mTORC2 exerts
its effects through Akt and is rapamycin-insensitive [16].
Therefore, most of the inhibitory effects of rapamycin are
attributable to the inhibition of signalling mediated by
mTORC1-S6K1 [16]. Evidence for a role of S6K1 in regulation
of mouse lifespan has been presented recently [13], suggesting that
the aging-modulating effect of mTOR is mediated through its
downstream effector S6K1. Although there is evidence for a role of
mTOR/S6K1 in vascular functions [17], only little information is
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available about the role of mTOR, particularly of S6K1, in aging-
associated vascular dysfunctions.
In particular, experiments analysing cardiovascular mTOR/
S6K1 activity in aging animal models yield inconsistent results. A
study using microarray analyses showed that gene expression
pattern associated with mTOR is suppressed upon aging in the
heart of Fischer 344 rats [18], suggesting that mTOR pathway is
down-regulated in aging. Another study, however, showed an
increased basal mTOR-mediated phosphorylation of S6K1 at
Thr389 in aortas of Fischer 344 x Brown Norway F1 hybrid rats
[19], which implicates an enhanced mTOR/S6K1 signalling in
aging.
It is now well recognized that resveratrol, a natural polyphenol,
exerts protective effects on vascular diseases, type II diabetes, and
aging in several animal species [20,21]. Although there is
substantial evidence suggesting that the beneficial effects of
resveratrol are attributed to activation of the class III histone
deacetylase (HDAC) Sirt1 [22], a recent rigorous study analysing
the pharmacological effects of resveratrol and Sirt1-activating
drugs has challenged this notion [23]. Moreover, Sirt1-indepen-
dent effects of resveratrol have also been reported [24–26]. At the
molecular level, it has been shown that resveratrol is able to inhibit
mTOR/S6K1 pathway in different cell types [24,25,27–29].
However, whether resveratrol improves endothelial function in
aging through inhibition of S6K1 is not known.
These findings prompted us to investigate whether S6K1 plays a
role in endothelial dysfunction in aging and whether resveratrol
protects against endothelial dysfunction through inhibition of
S6K1 signalling under the aging condition.
Results
Enhanced S6K1 activity, increased superoxide and
decreased nitric oxide (NO) levels in senescent
endothelial cells
To investigate the role of S6K1 in endothelial aging, we first
determined S6K1 activity in cultured young and senescent human
endothelial cells. The senescence status of the cells was confirmed
by higher number of cells which stained positively for senescence-
associated ß-galactosidase (SA-ß-gal, Fig. 1A). A significantly
higher S6K1 activity as measured by phosphorylation of its
substrate S6 at serine 235/236 (S6-S235/S236) was detected in
senescent cells when compared with young cells (Fig. 1B, n = 6,
p,0.01). The increased S6K1 activity in the senescent cells was
associated with an enhanced superoxide production and a
decreased NO level as detected by MitoSox and dihydroethidium
(DHE) staining, and by 4,5-diaminofluorescein diacetate (DAF-
2DA) staining, respectively (Fig. 2A to 2C). The eNOS protein
level was, however, significantly higher in senescent cells as
compared to young cells (Fig. 2D).
eNOS uncoupling in senescent endothelial cells
To examine whether the increased eNOS protein level with
dysfunctional enzymatic activity in senescent endothelial cells is
the result of eNOS uncoupling, experiments with low temperature
SDS-PAGE for detection of eNOS dimer/monomer were
performed. Indeed, eNOS monomer level was significantly higher
in the senescent endothelial cells as compared to the young cells,
which leads to a significant decrease in eNOS-dimer/monomer
ratio in the senescent cells (Fig. 3A, n = 4, p,0.05). Moreover, the
increased production of superoxide anion in the senescent cells as
detected by DHE staining was inhibited by the eNOS inhibitor L-
NAME (Fig. 3B). These results provide evidence for eNOS
uncoupling in senescent endothelial cells.
Causal role of S6K1 in eNOS uncoupling and endothelial
cell senescence
To test whether the enhanced S6K1 accounts for the increased
superoxide and decreased NO production in senescent endothelial
cells, S6K1 was knocked down by shRNA-mediated silencing.
Silencing S6K1 as demonstrated by decreased protein levels of
S6K1 (Fig. 4A) significantly reduced oxidative stress as detected
by MitoSox and DHE staining, and enhanced NO production as
detected by DAF-2DA staining in the senescent endothelial cells
(Fig. 4B).
Conversely, adenovirus-mediated ectopic expression of a
constitutively active S6K1 mutant (S6K1ca) in the young cells,
as validated by increased S6K1ca protein level and enhanced S6-
S235/S236 phosphorylation (Fig. 5A), induced premature cellular
senescence as shown by increased number of SA-ß-gal positive
Figure 1. Increased S6K1 activity in senescent endothelial cells.
(A) A representative SA-ß-gal staining of young and senescent HUVECs.
(B) Immunoblotting analysis of S6-S235/S236 (p-S6), total S6, and
tubulin protein levels in the young and senescent endothelial cells.
Quantification of the signals is shown in the lower panel. n = 6 in each
group. **p,0.01. Scale bar = 0.2 mm.
doi:10.1371/journal.pone.0019237.g001
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cells (Fig. 5B). An enhanced superoxide anion generation and
decreased NO production were also observed in cells overex-
pressing the active S6K1 mutant (Fig. 5C). Moreover, over-
expression of the active S6K1ca mutant in the young endothelial
cells also increased eNOS monomer level and decreased eNOS-
dimer/monomer ratio (Fig. 6A, n = 8). The enhanced superoxide
anion production in S6K1ca-overexpressing cells as assessed by
DHE staining was inhibited by the eNOS inhibitor L-NAME
(Fig. 6B, n = 8). The results demonstrate the causal role of S6K1
in eNOS uncoupling.
Resveratrol inhibits Akt/S6K1 and improves endothelial
function in senescent cells
In senescent endothelial cells, the enhanced S6K1 activity was
associated with an increased Akt activation, the upstream kinase of
mTOR/S6K1, as measured by phosphorylation level of Akt-S473
(Fig. 7). The increased activation of both Akt and S6K1 in the
senescent endothelial cells was inhibited by resveratrol (10 mmol/L,
1 hour) (Fig. 7). The role of Akt in S6K1 activation in endothelial
cells was further demonstrated by experiments with HA-tagged Akt
mutants. Over-expression of a constitutively active Akt mutant (m/
Figure 2. Increased oxidative stress in senescent endothelial cells. Fluorescent signals of (A) MitoSox, (B) DHE, and (C) DAF-2DA staining for
detection of mitochondrial, cytoplasmic superoxide generation (red) and NO production (green) in young and senescent HUVECs, respectively.
Quantification of the signals from four independent experiments of each group is shown in the corresponding lower panels. *p,0.05, **p,0.01 vs.
young cells. Scale bar = 0.2 mm. (D) Immunoblotting showing increased eNOS protein level in senescent cells. Quantification of eNOS protein level is
shown in the lower panel. n = 9 in each group. **p,0.01 vs. young cells.
doi:10.1371/journal.pone.0019237.g002
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p-Akt) in the young endothelial cells enhanced S6K1 activity as
measured by increased level of p-S6-S235/S236 (Fig. 8A), whereas
over-expression of a dominant negative mutant of Akt (Akt-KA) in
the senescent endothelial cells decreased S6K1 activity (Fig. 8B).
Furthermore, the higher superoxide production in the senescent
cells was blunted by resveratrol (10 mmol/L, 1 hour) as well as by
rapamycin (20 ng/ml, 1 hour) (Fig. 9A and 9B), while decreased
basal NO production in the senescent cells was restored by the two
compounds (Fig. 9C). It is to note that resveratrol and rapamycin
did not affect endothelial function in young cells (Fig. 9).
Increased S6K1 activity in aging rat aortas: inhibition by
resveratrol and rapamycin
We then further investigated whether the above observations in
cultured endothelial cells would also hold true in an aging animal
model. The endothelium of old WKY rats (20–24 months old) had
much stronger SA-ß-gal staining than that of young rats (1–3
months old) (Fig. 10A). As in the cell culture model, the S6K1
activity as assessed by measuring the level of S6-S235/S236
phosphorylation was significantly higher in the aortas of old WKY
rats when compared to those of young rats (Fig. 10B). Moreover,
the increased S6-S235/S236 phosphorylation level in the old rats
was reduced by treatment of aortas with resveratrol (10 mmol/L,
1 hour) as well as with rapamycin (20 ng/ml, 1 hour) (Fig. 10C).
Resveratrol and rapamycin inhibit oxidative stress and
improve NO levels in aging rat aortas
As compared to aortas of young rats, aortas of old rats displayed an
increase in superoxide production as visualized by MitoSox staining,
which was inhibited by treatment of the blood vessels with rapamycin
or resveratrol (Fig. 11). Moreover, a decreased NO production
detected by DAF-2DA staining in the aortas of old rats were
improved by resveratrol or rapamycin (Fig. 12A and 12B), while no
significant changes in NO production upon treatment were observed
in the young rats (Fig. 12A and 12B). As observed in senescent
endothelial cells, eNOS expression in aortas of old rats was also
significantly increased as compared with that of young rats
(Fig. 12C). Similar to the senescent endothelial cells in culture, a
much higher eNOS monomer levels were observed in the aortic
endothelium of old rats than that of the young rats (Fig. 13A).
Conversely, eNOS dimers were decreased in the old rat aortic
endothelium as compared to the young rats (Fig. 13A). Furthermore,
as compared to the young rats, the endothelial production of
superoxide anion in the aortas of old rats as assessed by en face DHE
staining was significantly increased, which was largely reduced by
treatment of the aortas with L-NAME (1 mmol/L, 1 hour,Fig. 13B).
Furthermore, the endothelium-dependent relaxations to acetyl-
choline (in the presence of 1 mmol/L indomethacin to inhibit
aging-associated production of vasoconstrictor prostanoids which
interferes with the effect of endothelium-derived NO [3] was
impaired as compared to young animals (Fig. 14A and 14B). The
endothelial function in old rats (not in young animals) was
significantly improved by ex vivo treatment of aorta with resveratrol
(10 mmol/L, 1 hour) or rapamycin (20 ng/ml, 1 hour) (Fig. 14A
and 14B, respectively), whereas smooth muscle function as
assessed by endothelium-independent relaxations to the NO-
donor sodium nitroprusside (SNP) in old rats was not affected by
either of the two compounds (Fig. 14C and 14D).
Discussion
In the present study, we provide evidence showing that
enhanced S6K1 signalling plays a causal role in endothelial aging
Figure 3. eNOS uncoupling in senescent endothelial cells. (A) Immunoblotting analysis of eNOS-dimers and -monomers in the young and
senescent HUVEC endothelial cells. Ponseau S staining served as loading control. Quantification of the eNOS-dimer/monomer is shown in the lower
panel. n = 4 in each group. *p,0.05. (B) DHE staining for detection of cytoplasmic superoxide generation in young and senescent endothelial cells
with or without pre-treatment of the cells with L-NAME (1 mmol/L) for 1 hour as indicated. Quantification of the signals from six independent
experiments of each group is shown in the corresponding lower panels. ***p,0.001 between indicated groups. Scale bar = 0.2 mm.
doi:10.1371/journal.pone.0019237.g003
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and endothelial dysfunction related to eNOS uncoupling in a cell
culture model and in a rat aging model. Furthermore, we
demonstrate a novel mechanism of the vasoprotective effects of
the polyphenol resveratrol in endothelial aging, namely improve-
ment of endothelial function in aging through inhibition of S6K1.
Persistent activation of mTOR/S6K1 signalling has been
shown to be associated with organism aging and aging-associated
pathologies such as cancer, left ventricular hypertrophy, obesity,
and muscle degeneration in animal models [5,6,13,14]. Converse-
ly, inhibition of mTOR or S6K1 extends lifespan and delays onset
of aging-associated disorders in animal models [5,6,13,14,30].
Although the role of mTOR/S6K1 in regulation of lifespan of
various organisms and animal models has been well documented,
it is, however, not known whether mTOR, particularly S6K1, is
involved in vascular endothelial aging and associated endothelial
dysfunction. We show here that S6K1 activity is indeed enhanced
in two models of vascular aging, namely in the senescent human
endothelial cells in culture and in aortas of old rats. Moreover, we
provide several lines of experimental evidence demonstrating that
hyperactive S6K1 signalling plays a causal role in endothelial
aging, oxidative stress, and decreased NO production: (a)
Inhibition of S6K1 either by the mTOR inhibitor rapamycin or
by S6K1 silencing in senescent endothelial cells reduced
mitochondrial superoxide generation (evidenced by MitoSox
staining) and enhanced NO production; (b) Treatment of aortas
of old rats but not young rats with rapamycin resulted in inhibition
of endothelial mitochondrial superoxide anion production and
enhancement of basal NO production as well as improvement of
endothelium-dependent relaxations to acetylcholine (stimulated
NO production), demonstrating a critical role of S6K1 in
endothelial oxidative stress and dysfunction in aging; (c) Over-
expression of a constitutively active S6K1 mutant (S6K1ca) in
young endothelial cells enhanced mitochondrial superoxide
generation and decreased NO production, and induced premature
senescence as demonstrated by increased number of SA-ß-gal
positive cells in culture.
Increased superoxide production is well recognized as a
mechanism for rapid inactivation of endothelial NO leading to
endothelial dysfunction [31]. Multiple sources have been reported
to contribute to enhanced superoxide production in endothelial
cells including activated NADPH oxidase, mitochondrial dysfunc-
tion, and uncoupled eNOS [31]. With MitoSox Red indicator for
specific detection of mitochondrial superoxide, we show here that
S6K1 induces mitochondrial superoxide generation. This finding
is in line with the role of mTOR in controlling mitochondrial ROS
generation as reported in other cell types [32,33]. The results of
Figure 4. Silencing S6K1 reduces superoxide and enhances NO production in senescent endothelial cells. Senescent HUVECs were
transduced either with rAd/U6-LacZshRNA as control or with rAd/U6-S6K1shRNA. Four days post transduction, cells were subjected to (A)
immunoblotting analysis to reveal the effective silencing of S6K1 and (B) MitoSox, DHE, and DAF-2DA staining. Quantification of the signals from four
independent experiments of each group is shown in the corresponding lower panels. ***p,0.001 vs. rAd/U6-LacZshRNA control cells. Scale
bar = 0.2 mm.
doi:10.1371/journal.pone.0019237.g004
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our present study demonstrate that mitochondrial ROS genera-
tion in aging is stimulated by persistent activation of S6K1.
Moreover, the enhanced DHE signal in senescent endothelial cells
suggests that hyperactive S6K1 is also capable of inducing
superoxide generation from other sources.
In support of this notion, we show that S6K1 also enhances
superoxide generation through eNOS uncoupling mechanism,
since over-expression of the constitutively active S6K1 mutant in
young endothelial cells leads to increased eNOS monomer level
and decreased eNOS dimer/monomer ratio which are linked to
eNOS uncoupling [34]. Most importantly, cytoplasmic superoxide
generation as detected by DHE in the cells over-expressing S6K1
active mutant is markedly enhanced, which is abolished by the
eNOS inhibitor L-NAME. Consistent with these results obtained
from young endothelial cells over-expressing the active S6K1
mutant, in the senescent cells as well as in the aortas of old rats, in
which S6K1 is hyperactive, an increased eNOS monomer level
and decreased eNOS dimer/monomer ratio are observed. The
associated increase in superoxide generation in the aging
endothelial cells as assessed by DHE staining is largely inhibited
by the eNOS inhibitor L-NAME. It is of note that eNOS protein
level is higher in senescent endothelial cells and also in old rat
aortas. Results on eNOS level in aging are controversial. Both
increase and decrease in eNOS level in aging has been reported
(see review article by Brandes et al. [2]). An increase in eNOS gene
expression with dysfunctional enzymatic activity has also been
demonstrated under several disease conditions such as atheroscle-
rosis and diabetes [35–40]. The discrepancy on eNOS level in
aging and the disease conditions is not clear and may depend on
the stage of aging and the diseases. It seems that at the early or
even advanced stage, eNOS level is not altered or even increased,
the enzymatic activity of eNOS is, however, dysfunctional. At the
Figure 5. Over-expression of an active S6K1 mutant enhances superoxide, decreases NO production and induces premature
senescence in young endothelial cells. Young HUVECs were transduced either with an empty rAd vector as control or with rAd/CMV-HA-S6K1-ca
(a constitutively active S6K1 mutant). (A) Immunoblotting analysis of expression of HA-S6K1-ca with anti-HA antibody or antibodies against S6-S235/
S236 (p-S6), total S6, and tubulin on day 2 of post transduction. (B) Four days post transduction, cells were subjected to SA-ß-gal staining. (C)
MitoSox, DHE, and DAF-2DA staining were performed on day 2 of post transduction. Quantification of the signals is shown in the corresponding
lower panels. n = 6. **p,0.01 and ***p,0.001 vs. control cells. Scale bar = 0.2 mm.
doi:10.1371/journal.pone.0019237.g005
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Figure 6. Over-expression of an active S6K1 mutant causes eNOS uncoupling in endothelial cells. Young HUVEC cells were transduced
either with an empty rAd vector as control or with rAd/CMV-HA-S6K1ca (a constitutively active S6K1 mutant). Two days post transduction, cells were
subjected to (A) Immunoblotting analysis of expression of eNOS-dimers, -monomers with anti-eNOS antibody, HA-S6K1-ca with anti-HA antibody.
Ponseau S staining served as loading control. Quantification of the eNOS-dimer/monomer ratio is shown in the lower panel. n = 8 in each group. (B)
DHE staining was performed 1 hour after L-NAME (1 mmol/L) treatment. Quantification of the signals is shown in the corresponding lower panels.
n = 8. **p,0.01 and ***p,0.001 between indicated groups. Scale bar = 0.2 mm.
doi:10.1371/journal.pone.0019237.g006
Figure 7. Resveratrol inhibits Akt and S6K1 signalling in senescent endothelial cells. Young or senescent HUVECs were treated with either
solvent or resveratrol (Resv, 10 mmol/L) for one hour. The cell lysates were then prepared and subjected to immunoblotting analysis of Akt-S473 (p-Akt),
total Akt, S6-S235/S236 (p-S6), and total S6. Quantification of the signals is shown in the lower panels. n = 6, ***p,0.001 between indicated groups.
doi:10.1371/journal.pone.0019237.g007
S6K1 and Endothelial Aging
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very end of the disease stage, eNOS gene expression is decreased
and contributes to the impairment of endothelial function
[35,38,39]. The underlying mechanisms of increased eNOS level
under the disease conditions and also in aging are not known. It
has been hypothesized that oxidative stress under the physiological
and pathological conditions may enhance eNOS level as a
counteracting defense mechanism [38,41,42]. In the current
study, we demonstrate that the higher eNOS level in aging
endothelial cells is due to increased eNOS monomer levels which
are enhanced by S6K1. The results together demonstrate that
S6K1 plays a causal role in eNOS uncoupling in aging. Since
activation of S6K1 leads to generation of superoxide from
mitochondrion and from uncoupled eNOS, further experiments
will be designed to investigate the relationship between mitochon-
drial dysfunction and eNOS uncoupling in aging.
It is well demonstrated that resveratrol exerts protective effects
on aging-associated pathologies in animal models [20,21] and
possesses anti-oxidative properties in endothelial cells as shown in
numerous previous studies including our own [43,44]. In
agreement with those studies, we show here that resveratrol
inhibits mitochondrial superoxide generation and increases
endothelial NO production in both aging models. Moreover, we
demonstrate that resveratrol exerts similar inhibitory effects on
S6K1 as rapamycin in the aortas of old rats. This is consistent with
our data obtained in cultured senescent endothelial cells and with
reports showing the inhibitory effect of resveratrol on S6K1
signalling in other cell types [24,25,27]. In view of the fact that
hyperactive S6K1 is both necessary and sufficient for increased
superoxide generation and decreased NO level in senescence/
aging as evidenced in our current study, these data suggest that the
beneficial effect of resveratrol on endothelial function in aging is at
least in part attributable to its property of inhibiting S6K1
signalling. While the basal release of NO (as detected by DAF-
2DA signal) can be fully restored by resveratrol and rapamycin,
the stimulated release of NO in response to acetylcholine (as
monitored in vascular reactivity study in a Multi-Myograph
System) in old rat aortas is only partially improved by the two
compounds. A probable explanation would be that additional
defects in eNOS function upon activation with acetylcholine exist
in aging. For example, co-factor i.e. BH4 deficiency seems to play
an important role in aging-associated endothelial dysfunction [45].
Studies indicate that some pharmacological effects of resveratrol
can be attributed to activation of the class III HDAC Sirt1 [22].
However, results from a recent study focusing on Sirt1 activity
challenged the concept that Sirt1 is the direct target of resveratrol
and related drugs [23]. In addition, increasing evidences have been
presented that not all effects of resveratrol can be explained by
stimulation of Sirt1. Sirt1-independent mechanisms have been
reported [24,25]. With respect to its inhibitory effect on mTOR/
S6K1 signalling, both Sirt1-dependent and Sirt1-independent
mechanisms have been demonstrated [46]. Evidences have been
presented that inhibition of Akt, an upstream signalling of mTOR/
S6K1 pathway, represents one of the mechanisms by which
resveratrol negatively regulates mTOR/S6K1 pathway [47,48].
Given that increased activity of Akt has been demonstrated to play a
role in endothelial cell senescence [49], it is noteworthy that the
increased S6K1 in senescence/aging in our current study is
associated with increased basal Akt activity as evident by the
increased phosphorylation of Akt. Moreover, resveratrol concomi-
tantly inhibits Akt and S6K1 in the senescent endothelial cells in
culture. These data suggest that the increased basal Akt activity
accounts at least in part for the enhanced S6K1 activity in senescent/
aging, and the inhibitory effect of resveratrol on S6K1 signalling may
be exerted at least in part through inhibition of Akt. Indeed, over-
Figure 8. Role of Akt in S6K1 activation in endothelial cells. (A) Young HUVEC cells were transduced either with an empty rAd vector as
control or with rAd/CMV-HA-m/p-Akt (a constitutively active Akt mutant). (B) Senescent HUVEC cells were transduced either with an empty rAd
vector as control or with rAd/CMV-HA-Akt-KA (a dominant negative Akt mutant). Two days post transduction, the cells were subjected to
immunoblotting analysis of expression of HA-tagged Akt mutants with anti-HA antibody, or with antibodies against S6-S235/S236 (p-S6) and total S6.
Quantification of the signals is shown in the lower panels. n = 4. **p,0.01 and ***p,0.001 between indicated groups.
doi:10.1371/journal.pone.0019237.g008
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Figure 9. Resveratrol reduces superoxide generation and enhances NO production in senescent endothelial cells. Young and
senescent HUVEC cells were treated with solvent as control (C), resveratrol (Resv, 10 mmol/L) or rapamycin (Rapa, 20 ng/ml) for one hour and then
subjected to (A) MitoSox, (B) DHE, and (C) DAF-2DA staining. Quantification of the signals from six independent experiments is shown in the
corresponding right panels. *p,0.05, **p,0.01 and ***p,0.001 between indicated groups. Scale bar = 0.2 mm.
doi:10.1371/journal.pone.0019237.g009
S6K1 and Endothelial Aging
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expression of a constitutively active Akt mutant (m/p-Akt) in the
young endothelial cells enhances S6K1 activity. Conversely, over-
expression of a dominant negative mutant of Akt decreases, although
not fully inhibits, S6K1 activity in the senescent endothelial cells.
These results provide direct evidence for a role of Akt in activation of
S6K1 in endothelial cells. An Akt-independent activation of S6K1
pathway in aging endothelial cells may also exist, which remains to
be investigated in future studies.
In summary, our study demonstrates a causal role of S6K1 in
eNOS uncoupling, endothelial oxidative stress, dysfunction, and
cellular senescence in aging. The beneficial effects of resveratrol on
vascular aging are at least partly mediated by inhibition of
endothelial S6K1. Thus, inhibition of S6K1 signalling may represent
a novel therapeutic approach for aging-associated vascular disease.
Methods
Ethics Statement
Animal work was approved by the Ethical Committee of
Veterinary Office of Fribourg (number 174/07), Switzerland and
was performed in compliance with guidelines on animal
experimentation at our institution.
Materials
All chemicals including those used for immunoblotting were
obtained from Sigma (Buchs, Switzerland) except the following: l-
norepinephrine bitartrate, acetylcholine (ACh), sodium nitroprusside
(SNP), trans-resveratrol were purchased fromCalbiochem; antibodies
against phospho-S6K1-T389 (9205), phospho-S6-S235/236 (2211s),
S6 (2217s) were from Cell Signalling (Allschwil, Switzerland);
Antibodies against S6K1 (9205s) was from BD Transduction
laboratories (Allschwil, Switzerland); Alexa Fluor680-conjugated
anti-mouse IgG (A21057), dihydroethidium (DHE), MitoSox red
mitochondrial superoxide indicator (MitoSox) were from Molecular
Probes/Invitrogen (Lucerne, Switzerland), and IRDye800-conjugat-
ed anti-rabbit IgG (926–32211) were from LI-CORBiosciences (Bad
Homburg, Germany); the membrane-permeable 4,5-diaminofluor-
esceine acetate (DAF-2DA) was from VWR international SA
(Dietikon, Switzerland); x-gal was from Promega; Endothelial cell
growth supplement (ECGS) pack was from PromoCell GmbH
(Allschwil, Switzerland) and all cell culture media and materials were
purchased from Gibco BRL (Lucerne, Switzerland).
Animals
Young (1 to 3 months old) and old (20 to 24 months) male WKY
rats (Harlan Netherlands) were maintained on a 12-h light-dark cycle
and fed standard chow diet and tap water according to the local
guidelines of animal experimentation. The animals were anesthetized
with xylazin (10 mg/kg body weight, intraperitoneally) and ketamin
(100 mg/kg body weight, intraperitoneally) and sacrificed. Thoracic
aortas were dissected and cleaned from perivascular fat, and subjected
to organ chamber experiments, en face staining or snap frozen directly
in liquid N2 and kept at 280uC till further biochemical analyses.
Figure 10. Increased S6K1 activity in aortas of old rats is
inhibited by resveratrol. (A) SA-ß-gal staining of the endothelium in
an aorta segment of a young and an old WKY rat. (B) Immunoblotting
analysis of S6-S235/S236 (p-S6) and total S6 in the aortas of young and
old rats (n = 9 of each group). (C) The aortas of old rats were treated ex
vivo with solvent as control (C), resveratrol (Resv, 10 mmol/L) or
rapamycin (Rapa, 20 ng/ml) in Krebs-Ringer bicarbonate solution (37uC,
95% O2/5% CO2) for one hour. The lysates were prepared for
Immunoblotting analysis of S6-S235/S236 (p-S6) and total S6 levels
(n = 3). *p,0.05 and **p,0.01 between indicated groups.
doi:10.1371/journal.pone.0019237.g010
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Recombinant adenoviral (rAd) expressing short hairpin
RNA (shRNA), S6K1 or Akt
rAd expressing shRNA targeting human S6K1 driven by the U6
promoter (rAd/U6-S6K1shRNA) and rAd/CMV-HA-S6K1ca (a
constitutively active S6K1 mutant F5A-E389-R3A), -HA-m/p-Akt
(a constitutively active Akt mutant) and –HA-Akt-KA (a dominant
negative Akt mutant) were described previously [17,50,51]. The
control rAd expressing LacZshRNA and the empty rAd were from
Invitrogen life Technologies.
Senescence-associated ß-galactosidase (SA-ß-gal)
staining
Cells were initially washed twice with PBS followed by fixation
with 2% formaldehyde solution in PBS for 10–15 min. After
washing twice with PBS, cells were then incubated with the SA-ß-
gal staining solution (1 mg/ml X-gal, 40 mmol/L citric acid,
5 mmol/L potassium ferrocyanide, 5 mmol/L potassium ferricy-
anide, 150 mmol/L sodium chloride, 2 mmol/L magnesium
chloride dissolved in phosphate buffer, pH 6.0) overnight at
Figure 11. Inhibition of S6K1 suppresses superoxide generation in the aortas of old rats. Confocal microscopic en face detection of
MitoSox staining for mitochondrial superoxide anion production followed by counterstaining with DAPI for endothelial nuclei in the intact thoracic
aorta segments from young and old rats, which were treated with resveratrol (Resv) or rapamycin (Rapa) as described in Fig. 10. The upper panels
show representative images from a young and an old rat and lower panel shows quantification of the fluorescence intensity from three animals in
each group. Scale bar = 50 mm. ***p,0.001 between indicated groups.
doi:10.1371/journal.pone.0019237.g011
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37uC in a CO2-free atmosphere. The stained senescent cells were
detected by conventional microscopy.
Endothelial cell culture and adenoviral transduction of
the cells
Human umbilical vein endothelial cells (HUVEC) [36] were
maintained in RPMI-1640 medium supplemented with 5% FCS
and ECGS. Cells of passage 1 to 2 (P1 to P2) were used as young
cells. Some of the cells were further splitted in a ratio of 1:3
continuously over a period of several weeks till replicative
senescence was reached as assessed by SA-ß-gal staining (P9 to
P12). Transduction of HUVECs by recombinant adenovirus was
performed as previously described [51]. Cells were transduced
with the recombinant adenovirus at titers of 100 Multiplicity Of
Infection (MOI) and cultured in complete medium for 2–4 days
before experiments as indicated in the figures.
Immunoblotting
Cell or tissue lysate preparation, SDS-PAGE, transfer of SDS
gels to an Immobilon-P membranes (Millipore) were performed as
previously described [36]. The resultant membrane was first
incubated with the corresponding primary antibody at room
Figure 12. Inhibition of S6K1 increases NO production in the aortas of old rats. (A) Confocal microscopic en face detection of DAF-2DA
staining for endothelial NO production followed by counterstaining with DAPI for endothelial nuclei in the intact thoracic aorta segments from young
and old rats, which were treated with resveratrol (Resv) or rapamycin (Rapa) as described in Fig. 7. Shown are representative images from a young
and an old rat. (B) Quantification of the fluorescence intensity from three animals in each group. Scale bar = 250 mm. ***p,0.001 between indicated
groups. (C) Immunoblotting analysis of eNOS protein levels in aortas of young and old rats. Quantification of the signals is shown in the lower panel.
n = 5, **p,0.01 vs. young rats.
doi:10.1371/journal.pone.0019237.g012
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temperature for 2 hours with gentle agitation after blocking with
5% skimmed milk. The blot was then further incubated with a
corresponding anti-mouse (Alexa fluor 680 conjugated) or anti-
rabbit (IRDye 800 conjugated) secondary antibodies. Signals were
visualized using Odyssey Infrared Imaging System (LI-COR
Biosciences). Quantification of the signals was performed using
NIH Image 1.62 software.
Detection of eNOS-monomer and dimer in cultured
endothelial cells and the endothelium from rat aortas
Low-temperature SDS-PAGE (LT-PAGE) was performed for
detection of SDS-resistant eNOS dimer and monomer as
described previously [52]. Briefly, cultured endothelial cells or
the endothelial layers isolated from rat thoracic aortas treated with
collagenase (collagenase type IA, 1 mg/ml in RPMI for 20 min)
were harvested in the cold extraction buffer as described above for
immunoblotting. Equal amount of protein of each sample was
treated with 1xLaemmli buffer without 2-mercaptoethanol or
DTT on ice and subjected to 6%SDS-PAGE at 4uC in a cold
room. Subsequent to LT-PAGE, immnunoblotting was performed
with anti-eNOS antibody as described above.
Activity of S6K1
Activity of S6K1 was analyzed by monitoring phosphorylation
of its substrate S6 at serine235/serine236 (S235/S236) by
immunoblotting.
Detection of NO and superoxide level in cultured
endothelial cells
For detection of NO, HUVECs were gently washed twice with
Ca2+-free PBS, and incubated in a modified Krebs-Ringer
bicarbonate solution (in mmol/L, NaCl 118, KCl 4.7, CaCl2
2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, EDTA 0.026, and
glucose 5.5) containing 5 mmol/L of DAF-2DA for 30 minutes.
For measurement of superoxide, cells were incubated with
5 mmol/L DHE for 20 minutes or 5 mmol/L MitoSox for
10 minutes for detection of cytoplasmic or mitochondrial
superoxide, respectively. For functional eNOS uncoupling study,
Figure 13. eNOS uncoupling in the aortas of old rats. (A) Immunoblotting analysis of eNOS-dimers and –monomers in the aortic endothelium
of young and old rats. Ponseau S staining served as loading control. Quantification of the eNOS-dimer/monomer ratio is shown in the lower panel.
n = 3 in each group. (B) Confocal microscopic en face detection of DHE staining for cytoplasmic superoxide anion production followed by
counterstaining with DAPI for endothelial nuclei in the intact thoracic aorta segments from young and old rats, which were treated with or without L-
NAME (1 mmol/L, 1 hour). Shown are representative images from a young and an old rat. (C) Quantification of the fluorescence intensity from three
animals in each group. Scale bar = 50 mm. *p,0.05, **p,0.01, ***p,0.001 between indicated groups.
doi:10.1371/journal.pone.0019237.g013
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cells were pre-treated with the eNOS inhibitor L-NAME
(1 mmol/L) for 1 hour before DHE was added. The cells were
then washed 3 times and images were obtained with Zeiss
fluorescence microscopy. The intensity of the fluorescence was
quantified by Image J software (U. S. National Institutes of
Health).
en face Detection of NO and superoxide in rat aortas
NO and mitochondrial superoxide production in the absence or
presence of resveratrol or rapamycin was assessed with DAF-2DA
and MitoSox staining, respectively. Briefly, young (1–3 months)
and old rat (20–24 months) aortas cleaned of perivascular tissues
were equilibrated for 30 minutes in Krebs buffer at 37uC aerated
with 95% O2 and 5% CO2. After equilibration, resveratrol
(10 mmol/L) and rapamycin (20 ng/ml) were added to respective
blood vessels for 1 hour. DAF-2DA (5 mmol/L) or MitoSox
(5 mmol/L) was then added for 30 minutes or 10 minutes,
respectively. For functional eNOS uncoupling study, aortas of
young and old rats were treated as above described, except that L-
NAME (1 mmol/L) was added to respective blood vessels for
1 hour followed by staining with DHE (5 mmol/L) for 20 minutes.
The aortas were then washed three times and fixed in 4%
paraformaldehyde followed by counterstaining with DAPI
(300 nmol/L for 3 minutes). After washing with Krebs buffer,
the aortas were carefully cut longitudinally and mounted en face
(face down) on slides and then covered with cover slip for
endothelial layer imaging. Vectashield mounting medium was
used to preserve the fluorescence. The fluorescence was analyzed
in a Leica DM6000 confocal microscope within hours after
preparation. Fluorescence from DAF-2DA staining was excited
with 488 nm argon laser with emission detection at 500–535 nm,
whereas fluorescence from MitoSox was detected at 590 nm
emission. Z-scanning was done for each sample. After the signal on
the top (endothelial layer on the lumen border) of the sample was
observed, the images were collected. Three consecutive images per
field, acquired through the full thickness of endothelial signal, were
recorded for analysis. At least 3 different fields per sample were
evaluated. The images from DAF-2DA, MitoSox and DAPI
staining were quantified with Image J software and results are
presented as the ratio of DAF-2DA and DAPI positive nucleus or
ratio of MitoSox and DAPI.
Endothelium-dependent and -independent relaxations
Aortas were isolated from young and old rats and cleaned of
perivascular tissues as described [43]. Briefly, the aortas with
endothelium were cut into rings (3 mm in length) and suspended
in a modified Krebs-Ringer bicarbonate solution aerated with 95%
O2 and 5% CO2 at 37uC in a Multi-Myograph System (Model
Figure 14. Inhibition of S6K1 signalling improves vascular endothelial function in old rats. (A and B) Endothelium-dependent
relaxations to acetylcholine in aortas of old (O) and young (Y) rats (in the presence of indomethacin 1 mmol/L to eliminate endothelium-derived
contracting prostanoids in aging) in the absence or presence of resveratrol (Resv, 10 mmol/L, for 1 hour) or rapamycin (Rapa, 20 ng/ml, for 1 hour),
respectively. (C and D) Endothelium-independent relaxations in response to the NO-donor sodium nitroprusside (SNP) in aortas of old rats (O) in the
absence or presence of either of the two drugs. n = 5 to 7; *p,0.05 between O and O+Resv or O+Rapa;# p,0.05 between old (O) and young (Y) rats.
doi:10.1371/journal.pone.0019237.g014
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610 M, Danish Myo Technology A/S, Denmark) in parallel. The
aortic rings were allowed to equilibrate for 45 minutes and
progressively stretched to a passive tension of 10 mN that gives
the optimal length–tension relationship. To study the effects of
resveratrol or rapamycin on endothelium-dependent or indepen-
dent relaxations, one ring was incubated with vehicle as control, the
others were treated with either resveratrol (10 mmol/L) or
rapamycin (20 nmol/L) for 1 hour. The aortic rings were then
contracted with norepinephrine (0.3 mmol/L). After the contraction
induced by norepinephrine reached plateau, cumulative concen-
tration-responses to acetylcholine (ACh; 1 nmol/L to 10 mmol/L)
or to the NO donor sodium nitroprusside (SNP; 0.1 nmol/L to
10 mmol/L) were performed in each aortic ring. Indomethacin
(1 mmol/L) was added to the aortic rings throughout the whole
experiments to prevent any generation of endothelium-derived
contracting prostanoids.
Statistics
Data are given as mean6SEM. In all experiments, n represents
the number of experiments or animals. Statistical analysis was
performed with unpaired t test or ANOVA with Dunnett or
Bonferroni post-test. For analysis of vascular relaxations to ACh in
isolated aortas, relaxation responses to the same concentration of
ACh among the different aortic rings were compared. Statistical
analysis was performed using ANOVA with Bonferroni post-test.
Differences in mean values were considered significant at p,0.05.
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